Can a simple blood test predict lung cancer treatment outcomes?

NCT ID NCT07244016

Recruiting now Knowledge-focused Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether a technology that analyzes immune system T cells can predict how well a combination of the drug tislelizumab and standard chemotherapy works for people with extensive-stage small cell lung cancer. Researchers will enroll 40 patients who have not yet been treated. The goal is to see if certain T cell patterns can forecast how long a patient goes without their cancer worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help doctors predict which lung cancer patients will benefit most from this combination therapy, personalizing treatment.
What could go wrong: This is a small, early observational study with only 40 participants, so results may not apply to everyone. It is designed to gather information, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EXTENSIVE-STAGE SMALL CELL LUNG CANCER

Contacts and locations

Locations

Henan Cancer Hosipital
RECRUITING

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.